Preferred Label : KRAS G12D Inhibitor LY3962673;
NCIt synonyms : KRAS G12D-mutant Inhibitor LY3962673;
NCIt definition : An orally bioavailable inhibitor of the oncogenic KRAS substitution mutation G12D,
with potential antineoplastic activity. Upon oral administration, KRAS G12D inhibitor
LY3962673 specifically targets and noncovalently binds to KRAS G12D. This prevents
KRAS G12D-mediated signaling and activation of downstream survival pathways. This
leads to an inhibition of the growth of tumor cells that overexpress KRAS G12D. KRAS,
a member of the RAS family of oncogenes, serves an important role in cell signaling,
division and differentiation. Mutations of KRAS may induce constitutive signal transduction
leading to tumor cell proliferation, invasion, and metastasis. LY3962673 has a higher
affinity binding to the GDP-bound conformation of KRAS G12D compared to the GTP-bound
form.;
Molecule name : LY 3962673; LY-3962673;
Origin ID : C211591;
concept_is_in_subset
- has_target
